Use my Search Websuite to scan PubMed, PMCentral, Journal Hosts and Journal Archives, FullText. Kick-your-searchterm to multiple Engines kick-your-query now !>

A dictionary by aggregated review articles of nephrology, medicine and the life sciences Your one-stop-run pathway from word to the immediate pdf of peer-reviewed on-topic knowledge.

10.1128/AAC.01237-21 http://scihub22266oqcxt.onion/10.1128/AAC.01237-21 34181475!8370226!34181475     free     free     free Warning: file_get_contents(https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pubmed&id=34181475&cmd=llinks): Failed to open stream: HTTP request failed! HTTP/1.1 429 Too Many Requests in C:\Inetpub\vhosts\kidney.de\httpdocs\pget.php on line 215       Antimicrob+Agents+Chemother 2021 ; 65 (9): e0123721 Nephropedia Template TP {{tp|p=34181475|t=2021. Pharmacokinetics and Safety of XAV-19, a Swine Glyco-humanized Polyclonal Anti-SARS-CoV-2 Antibody, for COVID-19-Related Moderate Pneumonia: a Randomized, Double-Blind, Placebo-Controlled, Phase IIa Study |pdf=|usr=}}{{34181475}} gab.com Text Pharmacokinetics and Safety of XAV-19, a Swine Glyco-humanized Polyclonal Anti-SARS-CoV-2 Antibody, for COVID-19-Related Moderate Pneumonia: a Randomized, Double-Blind, Placebo-Controlled, Phase IIa Study JO: Antimicrob Agents Chemother http://www.kidney.de/pget.php?&tw=1&pmid=34181475 #FOAvip We assessed the pharmacokinetics and safety of XAV-19, a swine glyco-humanized polyclonal antibody against severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2), in coronavirus disease 2019 (COVID-19)-related moderate pneumonia. The objective was to evaluate the optimal dose and safety of XAV-19 during this first administration to patients with COVID-19-related moderate pneumonia. In this phase IIa trial, adults with COVID-19-related moderate pneumonia with a duration of </=10 days were randomized to receive an infusion of XAV-19 at 0.5 mg/kg of body weight at day 1 and day 5 (group 1), 2 mg/kg at day 1 and day 5 (group 2), or 2 mg/kg at day 1 (group 3) or placebo. Eighteen patients (n = 7 for group 1, n = 1 for group 2, n = 5 for group 3, and n = 5 for placebo) were enrolled. Baseline characteristics were similar across groups; median XAV-19 serum concentrations (ranges) at the time of the maximum serum concentration of the drug (C(max)) and at day 8 were 9.1 (5.2 to 18.1) and 6.4 (2.8 to 11.9) mug/ml, 71.5 and 47.2 mug/ml, and 50.4 (29.1 to 55.0) and 20.3 (12.0 to 22.7) mug/ml for groups 1, 2, and 3, respectively (P = 0.012). The median terminal half-life (range) was estimated at 11.4 (5.5 to 13.9) days for 2 mg/kg of XAV-19 at day 1. Serum XAV-19 concentrations were above the target concentration of 10 mug/ml (2-fold the in vitro 100% inhibitory concentration [IC(100)]) from the end of perfusion to more than 8 days for XAV-19 at 2 mg/kg at day 1. No hypersensitivity or infusion-related reactions were reported during treatment, and there were no discontinuations for adverse events and no serious adverse events related to the study drug. A single intravenous dose of 2 mg/kg of XAV-19 demonstrated high serum concentrations, predictive of potent durable neutralizing activity with good tolerability. (This study has been registered at ClinicalTrials.gov under identifier NCT04453384.). Twit Text FOAVip Pharmacokinetics and Safety of XAV-19, a Swine Glyco-humanized Polyclonal Anti-SARS-CoV-2 Antibody, for COVID-19-Related Moderate Pneumonia: a Randomized, Double-Blind, Placebo-Controlled, Phase IIa Study ????Antimicrob Agents Chemother http://www.kidney.de/pget.php?&tw=1&pmid=34181475 #FOAvip Twit Text # Free Paper on # # # # # LINK http://www.kidney.de/pget.php?&tw=1&pmid=34181475 #FOAvip English Wikipedia <ref>{{Cite pmid|34181475}}</ref> Pharmacokinetics and Safety of XAV-19, a Swine Glyco-humanized Polyclonal Anti-SARS-CoV-2 Antibody, for COVID-19-Related Moderate Pneumonia: a Randomized, Double-Blind, Placebo-Controlled, Phase IIa Study #MMPMID34181475 Gaborit B; Dailly E; Vanhove B; Josien R; Lacombe K; Dubee V; Ferre V; Brouard S; Ader F; Vibet MA; Le Thuaut A; Danger R; Flet L; Omnes A; Berly L; Chiffoleau A; Jobert A; Duvaux O; Raffi F Antimicrob Agents Chemother 2021[Aug]; 65 (9): e0123721 PMID34181475show ga We assessed the pharmacokinetics and safety of XAV-19, a swine glyco-humanized polyclonal antibody against severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2), in coronavirus disease 2019 (COVID-19)-related moderate pneumonia. The objective was to evaluate the optimal dose and safety of XAV-19 during this first administration to patients with COVID-19-related moderate pneumonia. In this phase IIa trial, adults with COVID-19-related moderate pneumonia with a duration of |*COVID-19[MESH] |Adult[MESH] |Animals[MESH] |Double-Blind Method[MESH] |Humans[MESH] |SARS-CoV-2[MESH]Pharmacokinetics and Safety of XAV-19, a Swine Glyco-humanized Polyclo(epmc).pdf DeepDyve Pubget Overpricing